Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial

BACKGROUND:We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy.
METHODS:In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80-110mg/dL; n=14), while the control group received conventional glycemic control (range of 80-180mg/dL; n=15). The primary endpoint was POICs.
RESULTS:The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P= 0.027), mean glycemic variability (13.5±3.5% vs. 16.4±5.9%; P=0.038), and plasma interleukin-6 level (26.3±33.8 vs 98.3±89.1pg/ml; P=0.036) compared to the control group, but insulin dosage (27.0±13.4 vs. 10.2±16.2 U; P=0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8±0.2 vs. 0.6±0.3; P=0.021) were markedly higher in the AP group.
CONCLUSIONS:Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs.
SUMMARY:Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.